Physician profile
Beverly Tchang
NPI 1194067587
$120,397.71
in general payments reported to CMS, 2019-2025
14 companies · $71K in 2025
The $71K reported for 2025 was more than what 97% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,274 · 2020: $120 · 2021: $3,133 · 2022: $6,695 · 2023: $12K · 2024: $26K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $90K · Travel and Lodging: $16K · Food and Beverage: $3,113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $89,882.50 |
| Travel and Lodging | $16,181.47 |
| Food and Beverage | $3,112.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $72,632.04 | 2019-2025 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20,226.36 | 2025 | |
| Eli Lilly and Company | $16,273.72 | 2024-2025 | Zepbound |
| Amgen INC. | $4,586.72 | 2019-2025 | |
| F. Hoffmann-La Roche Ag | $2,700.00 | 2025 | |
| Madrigal Pharmaceuticals | $2,064.08 | 2025 | Rezdiffra |
| Pfizer INC. | $1,200.00 | 2025 | |
| Lilly USA, LLC | $284.77 | 2019-2025 | Zepbound, Mounjaro |
| Alexion Pharmaceuticals, INC. | $204.73 | 2021-2024 | Ultomiris |
| Shire North American Group INC | $125.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $38.57 | 2019 | |
| Intra-Sana Laboratories | $29.88 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Currax Pharmaceuticals LLC | $17.53 | 2024 | Contrave |
| Genentech, INC. | $14.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beverly Tchang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.